By Fineline Cube Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan‑KRAS inhibitor.
Regulatory Milestones
| Item | Detail |
|---|---|
| Company | Abbisko Therapeutics Co., Ltd. (HKG: 2256) |
| Product | ABSK211 (oral small‑molecule pan‑KRAS inhibitor) |
| Indication | Advanced solid tumors harboring KRAS alterations |
| NMPA IND Clearance | Announced 19 Aug 2026 |
| FDA IND Clearance | 7 Jul 2026 |
| Next Steps | Global clinical development of ABSK211 |
Drug Profile & Mechanism of Action
- Molecule: Oral, highly potent small‑molecule pan‑KRAS inhibitor
- Coverage: Broad‑spectrum activity against multiple KRAS alterations, including KRAS G12D, G12C, G12S, G12V, G13D, and KRAS wild‑type amplification
- Preclinical Evidence: Promising antitumor activity and favorable selectivity, both as monotherapy and in combination settings
- Positioning: Potential new therapeutic option for patients with solid tumors harboring KRAS alterations
Market Impact & Outlook
- Dual Regulatory Footprint: Back‑to‑back FDA and NMPA IND clearances within six weeks enable synchronized global clinical development of ABSK211 — a key differentiator for Chinese biotechs seeking worldwide reach.
- Broad KRAS Coverage: Targeting multiple KRAS mutations — including the notoriously difficult G12D — plus wild‑type amplification positions ABSK211 as a potentially differentiated asset in one of oncology’s most competitive and underserved target spaces.
- Combination Flexibility: Preclinical activity in combination settings suggests future development optionality alongside standard‑of‑care regimens in KRAS‑driven solid tumors.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, efficacy, and regulatory pathway of ABSK211. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory decisions, and competitive dynamics.-Fineline Info & Tech